Compare IND. SWIFT with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IND. SWIFT vs SUVEN PHARMACEUTICALS - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IND. SWIFT SUVEN PHARMACEUTICALS IND. SWIFT/
SUVEN PHARMACEUTICALS
 
P/E (TTM) x -2.9 41.3 - View Chart
P/BV x - 11.3 - View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 IND. SWIFT   SUVEN PHARMACEUTICALS
EQUITY SHARE DATA
    IND. SWIFT
Mar-21
SUVEN PHARMACEUTICALS
Mar-21
IND. SWIFT/
SUVEN PHARMACEUTICALS
5-Yr Chart
Click to enlarge
High Rs5525 0.9%   
Low Rs2103 1.8%   
Sales per share (Unadj.) Rs65.739.7 165.7%  
Earnings per share (Unadj.) Rs-5.512.1 -45.4%  
Cash flow per share (Unadj.) Rs0.513.4 4.0%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Avg Dividend yield %00.6 0.0%  
Book value per share (Unadj.) Rs-128.446.4 -276.7%  
Shares outstanding (eoy) m54.16254.57 21.3%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x0.17.9 0.7%   
Avg P/E ratio x-0.625.9 -2.4%  
P/CF ratio (eoy) x6.423.5 27.2%  
Price / Book Value ratio x06.8 -0.4%  
Dividend payout %016.5 0.0%   
Avg Mkt Cap Rs m18479,953 0.2%   
No. of employees `000NANA-   
Total wages/salary Rs m512762 67.1%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m3,56110,097 35.3%  
Other income Rs m152142 106.9%   
Total revenues Rs m3,71310,240 36.3%   
Gross profit Rs m4024,430 9.1%  
Depreciation Rs m327316 103.4%   
Interest Rs m522117 447.3%   
Profit before tax Rs m-2954,139 -7.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m31,053 0.3%   
Profit after tax Rs m-2983,086 -9.7%  
Gross profit margin %11.343.9 25.7%  
Effective tax rate %-1.125.4 -4.3%   
Net profit margin %-8.430.6 -27.4%  
BALANCE SHEET DATA
Current assets Rs m2,6526,665 39.8%   
Current liabilities Rs m7,0623,215 219.6%   
Net working cap to sales %-123.934.2 -362.4%  
Current ratio x0.42.1 18.1%  
Inventory Days Days153200 76.6%  
Debtors Days Days1,107370 299.0%  
Net fixed assets Rs m4,0649,097 44.7%   
Share capital Rs m108255 42.6%   
"Free" reserves Rs m-7,06011,554 -61.1%   
Net worth Rs m-6,95211,808 -58.9%   
Long term debt Rs m6,442356 1,809.9%   
Total assets Rs m6,71615,762 42.6%  
Interest coverage x0.436.5 1.2%   
Debt to equity ratio x-0.90 -3,074.3%  
Sales to assets ratio x0.50.6 82.8%   
Return on assets %3.320.3 16.4%  
Return on equity %4.326.1 16.4%  
Return on capital %-44.535.0 -127.1%  
Exports to sales %74.20-   
Imports to sales %5.00-   
Exports (fob) Rs m2,643NA-   
Imports (cif) Rs m176NA-   
Fx inflow Rs m2,6829,902 27.1%   
Fx outflow Rs m2601,369 19.0%   
Net fx Rs m2,4228,533 28.4%   
CASH FLOW
From Operations Rs m7723,834 20.1%  
From Investments Rs m-167-3,114 5.4%  
From Financial Activity Rs m-483-766 63.1%  
Net Cashflow Rs m122-45 -271.1%  

Share Holding

Indian Promoters % 55.6 60.0 92.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 14.2 -  
FIIs % 0.0 8.3 -  
ADR/GDR % 0.0 0.0 -  
Free float % 44.5 40.0 111.1%  
Shareholders   13,596 86,447 15.7%  
Pledged promoter(s) holding % 73.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IND. SWIFT With:   SUN PHARMA    LUPIN    CIPLA    AUROBINDO PHARMA    DR. REDDYS LAB    



Today's Market

Sensex, Nifty Recover from Day's Low to End Higher; Maruti Suzuki Hits New High Post Q3 Results(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended higher.

Related Views on News

SUVEN PHARMACEUTICALS 2020-21 Annual Report Analysis (Annual Result Update)

Sep 6, 2021 | Updated on Sep 6, 2021

Here's an analysis of the annual report of SUVEN PHARMACEUTICALS for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of SUVEN PHARMACEUTICALS. Also includes updates on the valuation of SUVEN PHARMACEUTICALS.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

More Views on News

Most Popular

Tata Steel vs SAIL: Which Stock is Better?(Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

These 5 Penny Stocks are Held by Rakesh Jhunjhunwala. Worth a Look?(Views On News)

Jan 18, 2022

Rakesh Jhunjhunwala is holding these penny stocks in his portfolio for several years now.

Tech Mahindra's CTC Acquisition: Too Expensive?(Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

Time to Buy Energy Stocks(Fast Profits Daily)

Jan 14, 2022

Energy is a sector that looks set to take off. It's time to get in.

5 Hidden Tata Group Companies to Add to Your Watchlist(Views On News)

Jan 18, 2022

Here's all you need to know about these five Tata group stocks that aren't as popular as the others.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IND. SWIFT SHARE PRICE


Jan 25, 2022 (Close)

TRACK IND. SWIFT

  • Track your investment in IND. SWIFT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IND. SWIFT WITH

MARKET STATS